CRISPR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. 

CEO
Samarth Kulkarni
CEOSamarth Kulkarni
Employees
393
Employees393
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2013
Founded2013
Employees
393
Employees393

CRSP Key Statistics

Market cap
5.01B
Market cap5.01B
Price-Earnings ratio
-9.41
Price-Earnings ratio-9.41
Dividend yield
Dividend yield
Average volume
2.74M
Average volume2.74M
High today
$54.77
High today$54.77
Low today
$48.50
Low today$48.50
Open price
$49.88
Open price$49.88
Volume
4.27M
Volume4.27M
52 Week high
$78.48
52 Week high$78.48
52 Week low
$30.04
52 Week low$30.04

Stock Snapshot

The current CRISPR(CRSP) stock price is $52.57, with a market capitalization of 5.01B. The stock trades at a price-to-earnings (P/E) ratio of -9.41.

During the trading session on 2025-11-15, CRISPR(CRSP) shares reached a daily high of $54.77 and a low of $48.50. At a current price of $52.57, the stock is +8.4% higher than the low and still -4.0% under the high.

Trading activity shows a volume of 4.27M, compared to an average daily volume of 2.74M.

The stock's 52-week range extends from a low of $30.04 to a high of $78.48.

The stock's 52-week range extends from a low of $30.04 to a high of $78.48.

CRSP News

Benzinga 4d
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

On Saturday, CRISPR Therapeutics AG (NASDAQ:CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9...

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial
TipRanks 5d
Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)

“This has been another strong quarter of execution and progress across our portfolio,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRI...

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
39.3%
Sell
3.6%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.